Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 3:51 PM
Ignite Modification Date:
2025-12-25 @ 1:57 PM
NCT ID:
NCT02768792
Group ID:
EG000
Title:
Single Arm Pembrolizumab
Description:
Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of High dose cytarabine (HiDAC) salvage induction chemotherapy. Subjects who have a response to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (beginning on day 1 of maintenance).Subjects who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
Deaths Number Affected:
32
Deaths Number At Risk:
None
Serious Number Affected:
14
Serious Number At Risk:
37
Other Number Affected:
37
Other Number At Risk:
37
Study:
NCT02768792
Results Section:
NCT02768792
Adverse Events Module:
NCT02768792